Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.jconrel.2013.01.035
Title: Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer
Authors: Mi, Y.
Zhao, J.
Feng, S.-S. 
Keywords: Anticancer drugs
Biodegradable copolymers
Cancer nanotechnology
Combination therapy
Nanomedicine
Taxanes
Issue Date: 2013
Source: Mi, Y., Zhao, J., Feng, S.-S. (2013). Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. Journal of Controlled Release 169 (3) : 185-192. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jconrel.2013.01.035
Abstract: We developed a nanocarrier system of herceptin-conjugated nanoparticles of D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate (TPGS)-cisplatin prodrug (HTCP NPs) for targeted co-delivery of cisplatin, docetaxel and herceptin for multimodality treatment of breast cancer of high human epidermal growth factor receptor 2 (HER2) overexpression. Co-polymers poly(lactic acid)-TPGS (PLA-TPGS) and carboxyl group-terminated TPGS (TPGS-COOH) were also added in the polymeric matrix to stabilize the prodrug nanoparticles and to facilitate herceptin conjugation. The HTCP NPs of high, moderate and low docetaxel versus cisplatin ratio were prepared by the nanoprecipitation method, which showed a pH-sensitive release for both anticancer drugs. The therapeutic effects of HTCP NPs were evaluated in vitro and compared with Taxotere® and cisplatin. The HTCP NPs of high docetaxel versus cisplatin ratio were found to have better efficacy than those of moderate and low docetaxel versus cisplatin ratio. The targeting effects of the HTCP NPs were demonstrated by a much lower IC50 value of 0.0201+0.00780+0.1629 μg/mL of docetaxel+cisplatin+herceptin for SK-BR-3 cells, which are of high HER2 overexpression, than that of 0.225+ 0.0875+ 1.827 μg/mL for NIH3T3 cells, which are of low HER2 overexpression, after 24 h incubation. The same design of TPGS prodrug nanoparticles can also be applied for targeted co-delivery of other hydrophilic and hydrophobic drugs. © 2013 Elsevier B.V. All rights reserved.
Source Title: Journal of Controlled Release
URI: http://scholarbank.nus.edu.sg/handle/10635/90300
ISSN: 01683659
DOI: 10.1016/j.jconrel.2013.01.035
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

80
checked on Mar 19, 2018

WEB OF SCIENCETM
Citations

75
checked on Mar 19, 2018

Page view(s)

36
checked on Mar 11, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.